These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 28395123)

  • 1. Focused ultrasound as a novel strategy for Alzheimer disease therapeutics.
    Meng Y; Volpini M; Black S; Lozano AM; Hynynen K; Lipsman N
    Ann Neurol; 2017 May; 81(5):611-617. PubMed ID: 28395123
    [No Abstract]   [Full Text] [Related]  

  • 2. Alzheimer's Disease Mechanisms and Emerging Roads to Novel Therapeutics.
    Sala Frigerio C; De Strooper B
    Annu Rev Neurosci; 2016 Jul; 39():57-79. PubMed ID: 27050320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Science to practice: opening the blood-brain barrier with focused ultrasound-a potential treatment for Alzheimer disease?
    Jolesz FA
    Radiology; 2014 Dec; 273(3):631-3. PubMed ID: 25420161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Which is a better target for AD immunotherapy, A beta or tau?
    Martin-Jones Z; Lasagna-Reeves C
    Alzheimer Dis Assoc Disord; 2008; 22(2):111-2. PubMed ID: 18525281
    [No Abstract]   [Full Text] [Related]  

  • 5. Focused ultrasound: crossing barriers to treat Alzheimer's disease.
    Burgess A; Aubert I; Hynynen K
    Ther Deliv; 2011 Mar; 2(3):281-6. PubMed ID: 22833998
    [No Abstract]   [Full Text] [Related]  

  • 6. [Role of the blood-brain barrier in Alzheimer's disease].
    Gosselet F; Candela P; Cecchelli R; Fenart L
    Med Sci (Paris); 2011 Nov; 27(11):987-92. PubMed ID: 22130026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GSK3: a possible link between beta amyloid peptide and tau protein.
    Hernández F; Gómez de Barreda E; Fuster-Matanzo A; Lucas JJ; Avila J
    Exp Neurol; 2010 Jun; 223(2):322-5. PubMed ID: 19782073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tau function and dysfunction in neurons: its role in neurodegenerative disorders.
    Avila J; Lim F; Moreno F; Belmonte C; Cuello AC
    Mol Neurobiol; 2002 Jun; 25(3):213-31. PubMed ID: 12109872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins.
    Dickey CA; Kamal A; Lundgren K; Klosak N; Bailey RM; Dunmore J; Ash P; Shoraka S; Zlatkovic J; Eckman CB; Patterson C; Dickson DW; Nahman NS; Hutton M; Burrows F; Petrucelli L
    J Clin Invest; 2007 Mar; 117(3):648-58. PubMed ID: 17304350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oleocanthal enhances amyloid-β clearance from the brains of TgSwDI mice and in vitro across a human blood-brain barrier model.
    Qosa H; Batarseh YS; Mohyeldin MM; El Sayed KA; Keller JN; Kaddoumi A
    ACS Chem Neurosci; 2015 Nov; 6(11):1849-59. PubMed ID: 26348065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clearing amyloid through the blood-brain barrier.
    Zlokovic BV
    J Neurochem; 2004 May; 89(4):807-11. PubMed ID: 15140180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers reflecting different facets of Alzheimer's disease.
    Zetterberg H
    Eur J Neurol; 2008 Nov; 15(11):1143-4. PubMed ID: 18973609
    [No Abstract]   [Full Text] [Related]  

  • 13. Alzheimer's Disease and Cognitive Frailty: Novel Therapeutic Technologies.
    D'Onofrio G; Yu Z; Forlenza OV
    Biomed Res Int; 2016; 2016():7242651. PubMed ID: 27525276
    [No Abstract]   [Full Text] [Related]  

  • 14. Blood-brain barrier and blood-cerebrospinal fluid barrier in normal and pathological conditions.
    Ueno M; Chiba Y; Murakami R; Matsumoto K; Kawauchi M; Fujihara R
    Brain Tumor Pathol; 2016 Apr; 33(2):89-96. PubMed ID: 26920424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes.
    Cummings J
    Clin Transl Sci; 2018 Mar; 11(2):147-152. PubMed ID: 28767185
    [No Abstract]   [Full Text] [Related]  

  • 16. Ultrasound and Microbubble-Mediated Blood-Brain Barrier Disruption for Targeted Delivery of Therapeutics to the Brain.
    O'Reilly MA; Hynynen K
    Methods Mol Biol; 2018; 1831():111-119. PubMed ID: 30051428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tau Proteins Cross the Blood-Brain Barrier.
    Banks WA; Kovac A; Majerova P; Bullock KM; Shi M; Zhang J
    J Alzheimers Dis; 2017; 55(1):411-419. PubMed ID: 27662303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for Alzheimer's disease.
    Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
    Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The hunt for brain Aβ oligomers by peripherally circulating multi-functional nanoparticles: Potential therapeutic approach for Alzheimer disease.
    Mancini S; Minniti S; Gregori M; Sancini G; Cagnotto A; Couraud PO; Ordóñez-Gutiérrez L; Wandosell F; Salmona M; Re F
    Nanomedicine; 2016 Jan; 12(1):43-52. PubMed ID: 26410276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical use of cerebrospinal fluid biomarkers in Alzheimer's disease.
    Zetterberg H; Lunn MP; Herukka SK
    Biomark Med; 2012 Aug; 6(4):371-6. PubMed ID: 22917139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.